Immunomic Therapeutics

Astellas Pharma, Immunomic Therapeutics collaborate

Friday, January 30, 2015

Immunomic Therapeutics, a company developing next-generation vaccines based on the LAMP-vax platform headquartered in Hershey, Pa., and Astellas Pharma of Tokyo have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics’ vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a phase I trial of JRC2-LAMP-vax in Japan as soon as it is ready.

[Read More]